Global Overactive Bladder Treatment Market Research Report 2017

Publisher Name :
Date: 09-Nov-2017
No. of pages: 115
Inquire Before Buying

This report studies Overactive Bladder Treatment in Global market, especially in North America, Europe, China, Japan, focuses on top manufacturers in global market, with revenue and market share for each manufacturer, covering

Astellas Pharma

Allergan

Pfizer

Teva (Activas)

Johnson & Johnson

Market Segment by Regions, this report splits Global into several key Regions, with consumption, revenue, market share and growth rate of Overactive Bladder Treatment in these regions, from 2012 to 2022 (forecast), like

North America

China

Europe

Japan

RoW

Split by Product Types, with revenue market share and growth rate of each type, can be divided into

Anticholinergics

Mirabegron

Botox

Split by applications, this report focuses on consumption, market share and growth rate of Overactive Bladder Treatment in each application, can be divided into

Idiopathic Overactive Bladder

Neurogenic Overactive Bladder

Global Overactive Bladder Treatment Market Research Report 2017

Table of Contents
1 Overactive Bladder Treatment Market Overview 1
1.1 Product Overview and Scope of Overactive Bladder Treatment 1
1.2 Overactive Bladder Treatment Segment by Types 2
1.2.1 Global Market Share of Overactive Bladder Treatment by Types 2
1.2.2 Anticholinergics 3
1.2.3 Mirabegron 4
1.2.4 Botox 4
1.3 Overactive Bladder Treatment Segment by Applications 5
1.3.1 Overactive Bladder Treatment Market Share by Applications 5
1.3.2 Idiopathic Overactive Bladder 6
1.3.3 Neurogenic Overactive Bladder 6
1.4 Global Overactive Bladder Treatment Market by Regions (2012-2022) 7
1.4.1 Global Overactive Bladder Treatment Revenue Market Size Comparison by Regions (2012-2022) 7
1.4.2 North America Overactive Bladder Treatment Status and Prospect (2012-2022) 8
1.4.3 Europe Overactive Bladder Treatment Status and Prospect (2012-2022) 9
1.4.4 Japan Overactive Bladder Treatment Status and Prospect (2012-2022) 10
1.4.5 China Overactive Bladder Treatment Status and Prospect (2012-2022) 11
1.4.6 RoW Overactive Bladder Treatment Status and Prospect (2012-2022) 12
1.5 Global Overactive Bladder Treatment Market Size (2012-2022) 13
2 Global Overactive Bladder Treatment Market Competition by Manufacturers/Brand 14
2.1 Global Overactive Bladder Treatment Revenue (M USD) and Share by Manufacturers (2012-2017) 14
2.2 Global Overactive Bladder Treatment Gross Margin by Manufacturers (2012-2017) 18
3 Global Overactive Bladder Treatment Revenue (M USD) by Regions (2012-2017) 20
3.1 Global Overactive Bladder Treatment Revenue (M USD) and Market Share (%) by Regions (2012-2017) 20
3.2 Global Overactive Bladder Treatment Revenue (M USD) and Gross Margin (%) (2012-2017) 25
3.3 North America Overactive Bladder Treatment Revenue (M USD) and Gross Margin (%) (2012-2017) 26
3.4 Europe Overactive Bladder Treatment Revenue (M USD) and Gross Margin (%) (2012-2017) 27
3.5 Japan Overactive Bladder Treatment Revenue (M USD) and Gross Margin (2012-2017) 28
3.6 China Overactive Bladder Treatment Revenue (M USD) and Gross Margin (%) (2012-2017) 29
3.7 RoW Overactive Bladder Treatment Revenue (M USD) and Gross Margin (%) (2012-2017) 30
4 Global Overactive Bladder Treatment Revenue Trend by Types 31
4.1 Global Overactive Bladder Treatment Revenue (M USD) and Market Share (%) by Types (2012-2017) 31
4.2 Global Overactive Bladder Treatment Revenue (M USD) and Growth Rate by Type (2012-2017) 36
5 Global Overactive Bladder Treatment Revenue Trend by Applications 38
5.1 Global Overactive Bladder Treatment Revenue (M USD) and Market Share (%) by Applications (2012-2017) 38
5.2 Global Overactive Bladder Treatment Revenue (M USD) and Growth Rate by Applications (2012-2017) 43
6 Global Overactive Bladder Treatment Market Forecast by Types and Applications (2017-2022) 45
6.1 Global Overactive Bladder Treatment Revenue Forecast by Type (2017-2022) 45
6.2 Global Overactive Bladder Treatment Revenue Forecast by Application (2017-2022) 46
7 Analysis of Overactive Bladder Treatment Industry Key Manufacturers 47
7.1 Astellas Pharma 47
7.1.1 Company Profile 47
7.1.2 Product Information 48
7.1.3 Revenue, Cost and Gross Margin 49
7.2 Allergan 50
7.2.1 Company Profile 50
7.2.2 Product Information 51
7.2.3 Revenue, Cost and Gross Margin 52
7.3 Pfizer 53
7.3.1 Company Profile 53
7.3.2 Product Information 54
7.3.3 Revenue, Cost and Gross Margin 55
7.4 Teva Pharmaceutical (Activas) 56
7.4.1 Company Profile 56
7.4.2 Product Information 57
7.4.3 Revenue, Cost and Gross Margin 58
7.5 Johnson & Johnson 59
7.5.1 Company Profile 59
7.5.2 Product Information 60
7.5.3 Revenue, Cost and Gross Margin 61
8 Overactive Bladder Treatment Drug Manufacturing Cost Analysis 62
8.1 Overactive Bladder Treatment Drug Raw Materials Analysis 62
8.2 Overactive Bladder Treatment Drug R&D Cost Analysis 62
8.2.1 Clinical Phase Costs 63
8.2.2 Capitalized Costs 64
8.3 Proportion of Manufacturing Cost Structure 65
8.3.1 Raw Materials 65
8.3.2 Labor Cost 66
8.3.3 Manufacturing Expenses 72
9 Industrial Chain, Sourcing Strategy and Downstream Buyers 74
9.1 Overactive Bladder Treatment Industrial Chain Analysis 74
9.2 Upstream Raw Materials Sourcing 75
9.3 Downstream Buyers 75
10 Marketing Strategy Analysis, Distributors/Traders 77
10.1.1 Direct Marketing 77
10.1.2 Indirect Marketing 77
10.1.3 Marketing Channel Development Trend 77
10.2 Market Positioning 78
10.2.1 Pricing Strategy 78
10.2.2 Brand Strategy 78
10.3 Distributors/Traders List 78
11 Market Effect Factors Analysis 80
11.1 Technology Progress/Risk 80
11.2 Consumer Needs/Customer Preference Change 80
11.3 Economic/Political Environmental Change 80
12 Global Overactive Bladder Treatment Market Forecast by Regions (2017-2022) 91
12.1 Global Overactive Bladder Treatment Revenue (M USD), Revenue (M USD) Forecast (2017-2022) 91
12.2 Global Overactive Bladder Treatment Revenue (M USD) Forecast by Regions (2017-2022) 91
12.2.1 North America Overactive Bladder Treatment Revenue Forecast (2017-2022) 93
12.2.2 Europe Overactive Bladder Treatment Revenue (M USD) and Revenue Forecast (2017-2022) 94
12.2.3 Japan Overactive Bladder Treatment Revenue (M USD) and Revenue Forecast (2017-2022) 95
12.2.4 China Overactive Bladder Treatment Revenue (M USD) and Revenue Forecast (2017-2022) 96
12.2.5 RoW Overactive Bladder Treatment Revenue (M USD) and Revenue Forecast (2017-2022) 97
13 Research Findings and Conclusion 98
14 Methodology and Data Source 99
14.1 Methodology/Research Approach 99
14.1.1 Research Programs/Design 99
14.1.2 Market Size Estimation 100
14.1.3 Market Breakdown and Data Triangulation 101
14.2 Data Source 102
14.2.1 Secondary Sources 102
14.2.2 Primary Sources 103
14.3 Disclaimer 104
14.4 Author List 105
List of Tables and Figures
Figure Picture of Overactive Bladder Treatment 1
Figure Global Overactive Bladder Treatment Revenue (M USD) Comparison by Types (Product Category) (2012-2022) 2
Figure Global Overactive Bladder Treatment Revenue Market Share (%) by Types in 2016 3
Figure Product Picture of Anticholinergics 3
Figure Product Picture of Mirabegron 4
Figure Product Picture of Botox 4
Figure Global Overactive Bladder Treatment Revenue (M USD) Comparison by Applications (2012-2022) 5
Figure Global Overactive Bladder Treatment Revenue Market Share (%) by Applications in 2016 6
Figure Global Overactive Bladder Treatment Revenue Market Size Comparison by Regions (2012-2022) 7
Figure North America Overactive Bladder Treatment Revenue (M USD) and Growth Rate (%) (2012-2022) 8
Figure Europe Overactive Bladder Treatment Revenue (M USD) and Growth Rate (%) (2012-2022) 9
Figure Japan Overactive Bladder Treatment Revenue (M USD) and Growth Rate (%) (2012-2022) 10
Figure China Overactive Bladder Treatment Revenue (M USD) and Growth Rate (%) (2012-2022) 11
Figure RoW Overactive Bladder Treatment Revenue (M USD) and Growth Rate (%) (2012-2022) 12
Figure Global Overactive Bladder Treatment Revenue (M USD) Status and Outlook (2012-2022) 13
Table Global Overactive Bladder Treatment Revenue (M USD) of Key Manufacturers (2012-2017) 14
Table Global Overactive Bladder Treatment Revenue Market Share (%) by Manufacturers (2012-2017) 14
Figure 2012 Overactive Bladder Treatment Revenue Market Share (%) by Manufacturers 15
Figure 2013 Overactive Bladder Treatment Revenue Market Share (%) by Manufacturers 15
Figure 2014 Overactive Bladder Treatment Revenue Market Share (%) by Manufacturers 16
Figure 2015 Overactive Bladder Treatment Revenue Market Share (%) by Manufacturers 17
Figure 2016 Overactive Bladder Treatment Revenue Market Share (%) by Manufacturers 17
Figure 2017 Overactive Bladder Treatment Revenue Market Share (%) by Manufacturers 18
Table Global Overactive Bladder Treatment Gross Margin by Manufacturers (2012-2017) 18
Figure 2016 Global Overactive Bladder Treatment Gross Margin by Manufacturers 19
Table Global Overactive Bladder Treatment Revenue (M USD) by Regions (2012-2017) 20
Table Global Overactive Bladder Treatment Revenue Market Share (%) by Regions (2012-2017) 20
Figure Global Overactive Bladder Treatment Revenue Market Share (%) by Regions (2012-2017) 21
Figure 2012 Global Overactive Bladder Treatment Revenue Market Share (%) by Regions 21
Figure 2013 Global Overactive Bladder Treatment Revenue Market Share (%) by Regions 22
Figure 2014 Global Overactive Bladder Treatment Revenue Market Share (%) by Regions 22
Figure 2015 Global Overactive Bladder Treatment Revenue Market Share (%) by Regions 23
Figure 2016 Global Overactive Bladder Treatment Revenue Market Share (%) by Regions 23
Figure 2017 Global Overactive Bladder Treatment Revenue Market Share (%) by Regions 24
Figure Global Overactive Bladder Treatment Revenue Market Size Comparison by Regions (2012-2017) 25
Figure North America Overactive Bladder Treatment Revenue Market Size Comparison by Regions (2012-2017) 26
Figure Europe Overactive Bladder Treatment Revenue Market Size Comparison by Regions (2012-2017) 27
Figure Japan Overactive Bladder Treatment Revenue Market Size Comparison by Regions (2012-2017) 28
Figure China Overactive Bladder Treatment Revenue Market Size Comparison by Regions (2012-2017) 29
Figure RoW Overactive Bladder Treatment Revenue Market Size Comparison by Regions (2012-2017) 30
Table Global Overactive Bladder Treatment Revenue (M USD) by Types (2012-2017) 31
Table Global Overactive Bladder Treatment Revenue Market Share (%) by Types (2012-2017) 31
Figure Revenue Market Share (%) of Overactive Bladder Treatment by Types (2012-2017) 32
Figure 2012 Revenue Market Share (%) of Overactive Bladder Treatment by Types 32
Figure 2013 Revenue Market Share (%) of Overactive Bladder Treatment by Types 33
Figure 2014 Revenue Market Share (%) of Overactive Bladder Treatment by Types 33
Figure 2015 Revenue Market Share (%) of Overactive Bladder Treatment by Types 34
Figure 2016 Revenue Market Share (%) of Overactive Bladder Treatment by Types 35
Figure 2017 Revenue Market Share (%) of Overactive Bladder Treatment by Types 35
Figure Global Anticholinergics Overactive Bladder Treatment Revenue (M USD) and Growth Rate (2012-2017) 36
Figure Global Mirabegron Overactive Bladder Treatment Revenue (M USD) and Growth Rate (2014-2017) 37
Figure Global Botox Overactive Bladder Treatment Revenue (M USD) and Growth Rate (2012-2017) 37
Table Global Overactive Bladder Treatment Revenue (M USD) by Applications (2012-2017) 38
Table Global Overactive Bladder Treatment Revenue Market Share (%) by Applications (2012-2017) 38
Figure Revenue Market Share (%) of Overactive Bladder Treatment by Applications (2012-2017) 39
Figure 2012 Revenue Market Share (%) of Overactive Bladder Treatment by Applications 39
Figure 2013 Revenue Market Share (%) of Overactive Bladder Treatment by Applications 40
Figure 2014 Revenue Market Share (%) of Overactive Bladder Treatment by Applications 40
Figure 2015 Revenue Market Share (%) of Overactive Bladder Treatment by Applications 41
Figure 2016 Revenue Market Share (%) of Overactive Bladder Treatment by Applications 41
Figure 2017 Revenue Market Share (%) of Overactive Bladder Treatment by Applications 42
Figure Global Idiopathic Overactive Bladder Treatment Revenue (M USD) and Growth Rate (2012-2017) 43
Figure Global Neurogenic Overactive Bladder Treatment Revenue (M USD) and Growth Rate (2014-2017) 44
Table Global Overactive Bladder Treatment Revenue Forecast by Type (2017-2022) 45
Figure Global Overactive Bladder Treatment Revenue Market Share (%) Forecast by Type (2017-2022) 45
Table Global Overactive Bladder Treatment Revenue Forecast by Application (2017-2022) 46
Figure Global Overactive Bladder Treatment Revenue Market Share by Application (2017-2022) 46
Table Astellas Pharma Company Profile 47
Table Overactive Bladder Treatment Information of Astellas Pharma (Vesicare) 48
Table Overactive Bladder Treatment Information of Astellas Pharma (Betanis / Myrbetriq / BETMIGA) 48
Table Overactive Bladder Treatment Revenue (M USD), Cost (M USD) and Gross Margin of Astellas Pharma (2012-2017) 49
Figure Overactive Bladder Treatment Revenue (M USD) and Market Share of Astellas Pharma (2012-2017) 50
Table Allergan Company Profile 50
Table Overactive Bladder Treatment Information of Allergan (Botox) 51
Table Overactive Bladder Treatment Revenue (M USD), Cost (M USD) and Gross Margin of Allergan (2012-2017) 52
Figure Overactive Bladder Treatment Revenue (M USD) and Market Share of Allergan (2012-2017) 53
Table Pfizer Company Profile 53
Table Overactive Bladder Treatment Information of Pfizer (Toviaz) 54
Table Overactive Bladder Treatment Information of Pfizer (Toviaz) 55
Table Overactive Bladder Treatment Revenue (M USD), Cost (M USD) and Gross Margin of Pfizer (2012-2017) 55
Figure Overactive Bladder Treatment Revenue (M USD) and Market Share of Pfizer (2012-2017) 56
Table Teva Pharmaceutical (Activas) Company Profile 56
Table Overactive Bladder Treatment Information of Teva Pharmaceutical (Oxytrol) 57
Table Overactive Bladder Treatment Revenue (M USD), Cost (M USD) and Gross Margin of Teva Pharmaceutical (Activas) (2012-2017) 58
Figure Overactive Bladder Treatment Revenue (M USD) and Market Share of Teva Pharmaceutical (Activas) (2012-2017) 59
Table Johnson & Johnson Company Profile 59
Table Overactive Bladder Treatment Information of Johnson & Johnson (Ditropan and Ditropan XL) 60
Table Overactive Bladder Treatment Revenue (M USD), Cost (M USD) and Gross Margin of Johnson & Johnson (2012-2017) 61
Figure Overactive Bladder Treatment Revenue (M USD) and Market Share of Johnson & Johnson (2012-2017) 61
Figure Typical Phases from Research to the Market for a Drug Candidate 63
Table Out-of-pocket Preclinical and Clinical Period Cost per Investigational Biopharmaceutical Compound 64
Table Capitalized Preclinical and Clinical Period costs per Investigational Biopharmaceutical Compound 65
Figure Manufacturing Cost Structure of Overactive Bladder Treatment Drug 65
Figure 2016 Manufacturing Labor Cost Per Hour in China as a Proportion of Those in Other Countries (%) 66
Figure Manufacturing Labor Costs in Select Provinces and Countries in 2016 67
Figure 2016 Global Manufacturing Competitiveness Index Rankings by Country 68
Figure US Nonfarm Unit Labor Cost 2014-2016 69
Figure United States Average Hourly Wages (USD/H) 2016-2017 69
Figure China Labor Cost Index 2014-2016 70
Figure China Average Yearly Wages 2006-2016 70
Figure Euro Area Labor Cost 2014-2016 71
Figure Japan Overview of Average Monthly Wages 2012-2017 (JPY Thousand/Month) 71
Figure 2016 Manufacturing Labor Cost Per Hour in China as a Proportion of Those in Other Countries (%) 72
Table 2016 Global Electricity Price of Industry (USD/KWh) by Country 72
Figure Overactive Bladder Treatment Industrial Chain Analysis 74
Table Major Buyers of Overactive Bladder Treatment 75
Table Distributors/Traders List 78
Figure Global GDP Growth Rate for 2016 81
Figure Malaysia GDP 2006-2016 (Billion USD) 81
Figure Brunei GDP 2006-2016 (Billion USD) 82
Figure Brazil GDP 2006-2016 (Billion USD) 82
Figure Brazil CPI Change 2016-2017 83
Figure Mexico GDP 2006-2016 (Billion USD) 83
Figure Mexico CPI Change 2012-2016 84
Figure USA GDP 2006-2016 (Billion USD) 84
Figure USA CPI Change 2016-2017 85
Figure EU GDP 2006-2016 (Billion USD) 85
Figure EU CPI Change 2012-2016 86
Figure Germany GDP 2006-2016 (Billion USD) 86
Figure UK GDP 2006-2016 (Billion USD) 87
Figure UK CPI Change 2016-2017 87
Figure Italy GDP 2006-2016 (Billion USD) 88
Figure Italy CPI Change 2016-2017 88
Figure Japan GDP 2006-2016 (Billion USD) 89
Figure Japan CPI Change 2012-2016 89
Figure China GDP 2006-2016 (Billion USD) 90
Figure China CPI Change 2016-2017 90
Figure Global Overactive Bladder Treatment Revenue (M USD) and Growth Rate (%) Forecast (2017-2022) 91
Table Global Overactive Bladder Treatment Revenue (M USD) Forecast by Regions (2017-2022) 91
Figure Global Overactive Bladder Treatment Revenue Market Share (%) Forecast by Regions (2017-2022) 92
Figure North America Overactive Bladder Treatment Revenue (M USD) and Growth Rate (%) Forecast (2017-2022) 93
Figure Europe Overactive Bladder Treatment Revenue (M USD) and Growth Rate (%) Forecast (2017-2022) 94
Figure Japan Overactive Bladder Treatment Revenue (M USD) and Growth Rate (%) Forecast (2017-2022) 95
Figure China Overactive Bladder Treatment Revenue (M USD) and Growth Rate (%) Forecast (2017-2022) 96
Figure RoW Overactive Bladder Treatment Revenue (M USD) and Growth Rate (%) Forecast (2017-2022) 97
Table Research Programs/Design for This Report 99
Figure Bottom-up and Top-down Approaches for This Report 101
Figure Data Triangulation 102
Table Key Data Information from Secondary Sources 103
Table Key Data Information from Primary Sources 104
  • Global and Regional Overactive Bladder Treatment Market Research Report 2017
    Published: 06-Dec-2017        Price: US 3500 Onwards        Pages: 144
    Summary Overactive bladder (OAB) is a bladder disorder that results in an abnormal urge to urinate, urinary frequency, and nocturia (voiding at night). Some patients may also experience urinary incontinence (involuntary loss of bladder control). Market Segment as follows: By Region - Asia-Pacific - North America - Europe - South America - Middle East & Africa By Type - Anticholinergics - Mirabegr......
  • Global Overactive Bladder Treatment Market Data Survey Report 2025
    Published: 29-Nov-2017        Price: US 1500 Onwards        Pages: 87
    Summary Overactive bladder (OAB) is a bladder disorder that results in an abnormal urge to urinate, urinary frequency, and nocturia (voiding at night). Some patients may also experience urinary incontinence (involuntary loss of bladder control). The global Overactive Bladder Treatment market will reach Volume Million USD in 2017 with CAGR xx% 2018-2025. The main contents of the report including: Global market size and forecast Regional market s......
  • Global and China Overactive Bladder Treatment Market Research by Company, Type & Application 2013-2025
    Published: 24-Nov-2017        Price: US 2000 Onwards        Pages: 93
    Summary Overactive bladder (OAB) is a bladder disorder that results in an abnormal urge to urinate, urinary frequency, and nocturia (voiding at night). Some patients may also experience urinary incontinence (involuntary loss of bladder control). Market Segment as follows: By Type - Anticholinergics - Mirabegron - Botox By Application - Idiopathic Overactive Bladder - Neurogenic Overactive Bladder......
  • Global Overactive Bladder Treatment Market Research Report 2011-2023
    Published: 21-Nov-2017        Price: US 1800 Onwards        Pages: 86
    Summary Overactive bladder (OAB) is a bladder disorder that results in an abnormal urge to urinate, urinary frequency, and nocturia (voiding at night). Some patients may also experience urinary incontinence (involuntary loss of bladder control). The global Overactive Bladder Treatment market will reach xxx Million USD in 2017 with CAGR xx% 2018-2023. The objective of report is to define, segment, and project the market on the basis of product type, application, and region, and to d......
  • Cystitis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Nov-2017        Price: US 2000 Onwards        Pages: 60
    DelveInsight's, Cystitis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017" report provides comprehensive insights about marketed and Phase III products for the Cystitis. The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country. It also provides a comprehensive understanding of the emerging Phase III therapies for Cystitis which can turn out to be future prospe......
  • Nocturnal Enuresis -Epidemiology Forecast to 2025
    Published: 01-Nov-2017        Price: US 2750 Onwards        Pages: 40
    DelveInsight "Nocturnal Enuresis - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Nocturnal Enuresis in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Nocturnal Enuresis prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associated with......
  • Urinary Incontinence - Market Insights, Epidemiology and Market Forecast -2023-7MM
    Published: 01-Nov-2017        Price: US 4950 Onwards        Pages: 77
    DelveInsight's "Urinary Incontinence - Market Insights, Epidemiology and Market Forecast-2023-7MM" Reports provides an overview of the disease and global market size of the Urinary Incontinence for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes historical and forecasted epidemiological data for the prevalent cases of Urinary Incontinence from 2013-2023. Urinary Incontinence is a multifactorial syndrome which occurs due to the failure of the storage ......
  • Interstitial Cystitis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Nov-2017        Price: US 2000 Onwards        Pages: 60
    DelveInsight's, Interstitial Cystitis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017" report provides comprehensive insights about marketed and Phase III products for the Interstitial Cystitis. The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country. It also provides a comprehensive understanding of the emerging Phase III therapies for Interstitial Cystitis......
  • Nocturnal Enuresis - Market Insights, Epidemiology and Market Forecast - 2025
    Published: 01-Nov-2017        Price: US 5750 Onwards        Pages: 70
    DelveInsight's "Nocturnal Enuresis - Market Insights, Epidemiology and Market Forecast - Market Insights, Epidemiology and Market Forecast - 2025" report provides an overview of the disease and in depth research related to Nocturnal Enuresis - Market Insights, Epidemiology and Market Forecast for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding of the patients affected, diagnosed patter......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs